Literature DB >> 21372039

Preventive effects of (-)-epigallocatechin gallate on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db Mice.

Masahito Shimizu1, Hiroyasu Sakai, Yohei Shirakami, Yoichi Yasuda, Masaya Kubota, Daishi Terakura, Atsushi Baba, Tomohiko Ohno, Yukihiko Hara, Takuji Tanaka, Hisataka Moriwaki.   

Abstract

Obesity and related metabolic abnormalities, including insulin resistance and a state of chronic inflammation, increase the risk of hepatocellular carcinoma. Abnormal activation of the insulin-like growth factor (IGF)/ IGF-1 receptor (IGF-1R) axis is also involved in obesity-related liver tumorigenesis. In the present study, we examined the effects of (-)-epigallocatechin gallate (EGCG), a major biologically active component of green tea, on the development of diethylnitrosamine (DEN)-induced liver tumorigenesis in C57BL/KsJ-db/db (db/db) obese mice. Male db/db mice were given tap water containing 40 ppm DEN for 2 weeks and then they received drinking water containing 0.1% EGCG for 34 weeks. At sacrifice, drinking water with EGCG significantly inhibited the development of liver cell adenomas in comparison with the control EGCG-untreated group. EGCG inhibited the phosphorylation of the IGF-1R, ERK (extracellular signal-regulated kinase), Akt, GSK-3β (glycogen synthase kinase-3β), Stat3, and JNK (c-Jun NH(2)-terminal kinase) proteins in the livers of experimental mice. The serum levels of insulin, IGF-1, IGF-2, free fatty acid, and TNF-α were all decreased by drinking EGCG, which also decreased the expression of TNF-α, interleukin (IL)-6, IL-1β, and IL-18 mRNAs in the livers. In addition, EGCG improved liver steatosis and activated the AMP-activated kinase protein in the liver. These findings suggest that EGCG prevents obesity-related liver tumorigenesis by inhibiting the IGF/IGF-1R axis, improving hyperinsulinemia, and attenuating chronic inflammation. EGCG, therefore, may be useful in the chemoprevention of liver tumorigenesis in obese individuals. Cancer Prev Res; 4(3); 396-403. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21372039     DOI: 10.1158/1940-6207.CAPR-10-0331

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  23 in total

1.  Chemoprevention against hepatocellular carcinoma.

Authors:  Jun-Ichi Okano; Yuki Fujise; Ryo Abe; Ryu Imamoto; Yoshikazu Murawaki
Journal:  Clin J Gastroenterol       Date:  2011-06-04

Review 2.  Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents.

Authors:  Hiroyasu Sakai; Yohei Shirakami; Masahito Shimizu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  Epigallocatechin-3-gallate inhibits angiotensin II-induced C-reactive protein generation through interfering with the AT1-ROS-ERK1/2 signaling pathway in hepatocytes.

Authors:  Jingjing Zhao; Juntian Liu; Xiaoming Pang; Xiaolu Zhang; Shuyue Wang; Di Wu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-08-04       Impact factor: 3.000

4.  Green tea polyphenol EGCG suppresses Wnt/β-catenin signaling by promoting GSK-3β- and PP2A-independent β-catenin phosphorylation/degradation.

Authors:  Sangtaek Oh; Jungsug Gwak; Seoyoung Park; Chung S Yang
Journal:  Biofactors       Date:  2014-10-29       Impact factor: 6.113

5.  Obesity, but not ethanol, promotes tumor incidence and progression in a mouse model of hepatocellular carcinoma in vivo.

Authors:  Kyle J Thompson; Ryan Z Swan; Tracy L Walling; David A Iannitti; Iain H McKillop; David Sindram
Journal:  Surg Endosc       Date:  2013-03-07       Impact factor: 4.584

Review 6.  Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis.

Authors:  Masahito Shimizu; Takuji Tanaka; Hisataka Moriwaki
Journal:  Semin Immunopathol       Date:  2012-09-04       Impact factor: 9.623

7.  C57BL/KsJ-db/db-Apc mice exhibit an increased incidence of intestinal neoplasms.

Authors:  Kazuya Hata; Masaya Kubota; Masahito Shimizu; Hisataka Moriwaki; Toshiya Kuno; Takuji Tanaka; Akira Hara; Yoshinobu Hirose
Journal:  Int J Mol Sci       Date:  2011-11-18       Impact factor: 5.923

Review 8.  Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis.

Authors:  Masahito Shimizu; Masaya Kubota; Takuji Tanaka; Hisataka Moriwaki
Journal:  Int J Mol Sci       Date:  2012-01-05       Impact factor: 6.208

9.  Metformin suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-+Leprdb/+Leprdb mice.

Authors:  Tomohiko Ohno; Masahito Shimizu; Yohei Shirakami; Atsushi Baba; Takahiro Kochi; Masaya Kubota; Hisashi Tsurumi; Takuji Tanaka; Hisataka Moriwaki
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

10.  Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy.

Authors:  Inyoung Kim; Yu-Ying He
Journal:  Front Oncol       Date:  2013-07-15       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.